<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01584037</url>
  </required_header>
  <id_info>
    <org_study_id>DR-501-401</org_study_id>
    <nct_id>NCT01584037</nct_id>
  </id_info>
  <brief_title>Adenovirus Vaccine Pregnancy Registry</brief_title>
  <official_title>Adenovirus Vaccine Pregnancy Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the Adenovirus Vaccine Pregnancy Registry is to prospectively collect&#xD;
      data concerning:&#xD;
&#xD;
        1. Pregnant women exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral,&#xD;
&#xD;
        2. Potential confounding factors, and&#xD;
&#xD;
        3. The outcome of these pregnancies.&#xD;
&#xD;
      The secondary purpose of the Adenovirus Vaccine Pregnancy Registry is to evaluate the&#xD;
      frequency of birth defects in prospectively enrolled pregnant women. This Registry is also&#xD;
      designed to detect any unusual patterns of birth defects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Adverse Pregnancy Outcome by observation</measure>
    <time_frame>12 months</time_frame>
    <description>Infants up to 12 months of age</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Adenovirus</condition>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <description>This is a prospective, observational, exposure-registration and follow-up study of pregnant women exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral and their live born offspring through the first year of life. The intent of the Adenovirus Vaccine Pregnancy Registry, Protocol DR-501-401, is to collect observational data on pregnancy outcomes, including birth defects, in women who were exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of:&#xD;
&#xD;
          1. Women previously or currently enrolled in the U.S. Military who received Adenovirus&#xD;
             Type 4 and Type 7 Vaccine, Live, Oral while pregnant or who conceived within 6 weeks&#xD;
             of vaccine administration, and&#xD;
&#xD;
          2. Infants born to females with confirmed exposure to Adenovirus Type 4 and Type 7&#xD;
             Vaccine, Live, Oral, followed through one year post delivery.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For women:&#xD;
&#xD;
          -  U.S. Military service member, present or former&#xD;
&#xD;
          -  Confirmed exposure to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral&#xD;
&#xD;
          -  Received Adenovirus Type 4 and Type 7 Vaccine, Live, Oral while pregnant or has an&#xD;
             estimated date of conception (DOC) within 6 weeks after receiving Adenovirus Type 4&#xD;
             and Type 7 Vaccine, Live, Oral&#xD;
&#xD;
          -  Positive Î²-hCG test or fetal ultrasound,and&#xD;
&#xD;
          -  Verbal and/or written informed consent obtained from the patient.&#xD;
&#xD;
        For live born offspring:&#xD;
&#xD;
          -  Infant born to a woman meeting the above inclusion criteria and enrolled in the&#xD;
             Registry, followed through one year post delivery, and&#xD;
&#xD;
          -  Verbal and/or written informed consent obtained from the mother of the infant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refuse to provide informed consent (verbal or written) to the&#xD;
             Institutional Review Board (IRB)-approved informed consent.&#xD;
&#xD;
          -  Females not exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral within the&#xD;
             inclusion criteria period.&#xD;
&#xD;
          -  Patients not willing to meet Registry study conditions and requirements.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vikki Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Syneos Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>INC Research, LLC (Registry Coordinating Center)</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>April 20, 2012</study_first_submitted>
  <study_first_submitted_qc>April 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2012</study_first_posted>
  <last_update_submitted>April 17, 2014</last_update_submitted>
  <last_update_submitted_qc>April 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adenovirus</keyword>
  <keyword>Adenovirus Type 4</keyword>
  <keyword>Adenovirus Type 7</keyword>
  <keyword>Adenovirus Type 4 and Type 7 Vaccine, Live, Oral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoviridae Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

